Provider review
Eden review: pricing, pharmacy, and evidence status
Released: · Last reviewed: · By Dr. Parmis
Eden offers GLP-1 medications through telehealth. Every price, credential and pharmacy claim below is labeled by evidence status and read date.
Eden's lowest price on file is $99/month (Month to month, no membership), read November 20, 2026 on its own page. It names its dispensing pharmacy. On November 20, 2026 it scored 85.2/100 on GLP Ranked's v4.1 rubric, #2 of 15.
Rank and score
Eden scores 85.2 of 100, #2 of 15 scored programs (November 20, 2026). The table shows every sub-check, the points earned and why; the methodology explains each one.
| ID | Category | Sub-check | Points | Note |
|---|---|---|---|---|
| PT1 | Pricing transparency | Drug price printed on the program's own page, read in the November 20, 2026 re-read | 5 of 5 | |
| PT2 | Pricing transparency | Price includes medication and care, or every required fee is printed beside it (2 if the program's own figures disagree) | 5 of 5 | |
| PT3 | Pricing transparency | Price at every dose knowable: same price at every dose, or a full dose ladder | 5 of 5 | |
| PT4 | Pricing transparency | Plan term and billing interval stated (2 if the program's own pages disagree) | 5 of 5 | |
| CO1 | Clinical oversight | Prescribing medical group named (9), network label (5), physician executive only (3), arrangement described (2) | 3 of 9 | names Dr. Halland Chen, M.D. (Chief Medical Innovation Officer); no medical group named |
| CO2 | Clinical oversight | Prescribers' licensure or certification stated | 3 of 3 | |
| CO3 | Clinical oversight | Clinical lead (medical director or chief medical officer) named with credential | 0 of 3 | the physician named is a Chief Medical Innovation Officer; no medical director or chief medical officer is named |
| PH1 | Pharmacy transparency | Dispensing pharmacy named (10), class described but not named (4), described only (2); brand-only programs whose pages say prescriptions go to the pharmacy you choose (10) | 10 of 10 | about page names GoGoMeds, Precision, Enovex and Absolute Pharmacy |
| PH2 | Pharmacy transparency | Pharmacy class (503A/503B) or licensure stated; brand-only programs that send prescriptions to your chosen pharmacy (5) | 5 of 5 | |
| SU1 | Support | Two or more contact channels published (4), one (2) | 4 of 4 | |
| SU2 | Support | How to cancel is stated | 3 of 3 | |
| SU3 | Support | Refund terms are stated (any stated condition under which money is refunded or credited) | 3 of 3 | |
| RD1 | Regulatory disclosure | Compounded products described as not FDA-approved; brand-only programs (5) | 5 of 5 | |
| RD2 | Regulatory disclosure | No open FDA warning letter in FDA's index (read November 20, 2026) | 0 of 5 | FDA warning letter 728279, June 8, 2026; no close-out posted |
| AC1 | Accessibility | Where it operates stated clearly (4); vague or conflicting statements (2) | 4 of 4 | |
| AC2 | Accessibility | Payment beyond a card stated (HSA/FSA or pay-later) | 3 of 3 | |
| AC3 | Accessibility | Can start month to month without a multi-month commitment | 3 of 3 | |
| AN | Total annual cost | semaglutide, 12 months: $1,188 (monthly: 12 × $99); benchmark $1,140 | 19.2 of 20 | 20 × benchmark ÷ cost |
| Total | 85.2 of 100 | |||
FDA record: FDA warning letter 728279, dated June 8, 2026 (False & Misleading Claims/Misbranded (Telehealth)). FDA's index showed no close-out letter when read on November 20, 2026. Under sub-check RD2 an open letter removes 5 points, for every program alike.
Strengths and limitations
Drawn from the sub-checks above, as read November 20-21, 2026.
- Strength: Drug price printed on the program's own page, read in the November 20, 2026 re-read.
- Strength: Price includes medication and care, or every required fee is printed beside it.
- Strength: Price at every dose knowable: same price at every dose, or a full dose ladder.
- Strength: Plan term and billing interval stated.
- Limitation: Prescribing medical group named: 3 of 9 (names Dr. Halland Chen, M.D. (Chief Medical Innovation Officer); no medical group named).
- Limitation: Clinical lead: 0 of 3 (the physician named is a Chief Medical Innovation Officer; no medical director or chief medical officer is named).
- Limitation: No open FDA warning letter in FDA's index: 0 of 5 (FDA warning letter 728279, June 8, 2026; no close-out posted).
- Limitation: total annual cost scores 19.2 of 20.
Pricing by plan
| Medication | Formulation | Plan | Price | Source | Evidence |
|---|---|---|---|---|---|
| tirzepatide | compounded injectable | Month to month, no membership | $129/mo | provider page · read 2026-11-20 | Provider reported |
| semaglutide | compounded injectable | Month to month, no membership | $99/mo | provider page · read 2026-11-20 | Provider reported |
1 price point for Eden appeared only in a third-party source and has been withheld from this table and from any ranking or total until captured directly from the provider. See the source ledger for the withheld record.
"Provider reported" means the figure comes from the company's own site or intake flow and has not been independently corroborated by GLP Ranked.
Clinical model
Physician executive only: “Dr. Halland Chen, M.D. Chief Medical Innovation Officer” (www.tryeden.com, read 2026-11-10)
Accreditation: we have not verified any accreditation or certification claim for Eden against the issuing body. If a program cites one (for example LegitScript), check the issuer's public lookup before you rely on it.
Pharmacy & compliance
Names a pharmacy network on its about page: GoGoMeds, Precision, Enovex and Absolute Pharmacy (read 2026-11-10) Pharmacy transparency is worth 15 of 100 points under our v4.1 rubric.
State availability
State-by-state availability is not independently verified.
Who this suits — and who it doesn't
Eden may suit patients who want a standard-dose program and value that the dispensing pharmacy is named up front.It is a weaker fit for patients who need written proof of pharmacy accreditation before paying; ask the company for it.
Terms to check before you pay: whether cancellation and refund terms were found on its pages is recorded in sub-checks SU2 and SU3 above (read November 21, 2026); published support response times: not published.
Sources
- FDA warning letter 728279 (False & Misleading Claims/Misbranded (Telehealth)) — Regulator letter, captured 2026-11-20
- FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current October 1, 2026) — Regulator page, captured 2026-11-20
- FDA: Compounding: Inspections, Recalls, and other Actions (content current October 22, 2026) — Regulator list, captured 2026-11-21
Cite this page
GLP Ranked. "Eden review: pricing, pharmacy, and evidence status." https://glpranked.com/providers/eden/
GLP Ranked. "Eden review: pricing, pharmacy, and evidence status." https://glpranked.com/providers/eden/